ModernMedicine Resource Center More Topics

Ocular Allergy Resource Center

Connecting allergy and osmolarityThe major type 1 immunologic hypersensitivity reaction involving the conjunctiva is commonly referred to as allergic conjunctivitis.
Differentiating ocular allergyOn the surface, eyecare providers may not fully appreciate the prevalence and complexity of ocular allergy and its clinical management; we learn that it is a relatively simple disease defined by ocular itch.
IL-1 receptor inhibitor fails on ocular itching endpointIsunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.
Alcaftadine superior in reducing itching from grass, tree pollensAlcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.
How palynology and aldehydes affect allergy treatmentAs technology leaps forward with medicine, it is prudent at times to appreciate how far we have come in managing and treating allergic eye disease. In fact, let us look back to the beginning in ancient Rome with the first recorded case of atopy. One of these authors, Suetonius, wrote with great detail in his biographical text De vita Caeserum about the distinctive lives of the first Roman emperors.
How to identify and treat allergic eye disease
How to identify and treat allergic eye diseaseAs optometry’s scope of practice has increased, optometrists have embraced allergic eye disease. Ocular allergies have multiple effects to patients in our practice. But, if allergies are unidentified because symptoms may not be present during office visits, patients may treat themselves.
New ocular allergy drug’s MOA targets inflammation
New ocular allergy drug’s MOA targets inflammationA new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.
What clinicians should know about ocular allergies
What clinicians should know about ocular allergiesThe arrival of spring also signals the onset of ocular allergy season. Clinicians can prepare by knowing and recognizing the symptoms in their patients, as well as being informed about the latest therapies for this diagnosis.
Getting to the root cause of ocular allergyBeing armed with as much information as possible about a patient’s ocular allergies can make a major difference in treatment decisions, whether for dry eye or scheduling of ocular surgery.
What punctal plug delivery of dexamethasone means for allergic conjunctivitisTreatment of chronic allergic conjunctivitis with a sustained-release dexamethasone resulted in better clinical results because of the sustained and controlled delivery.